Evidence map›Paper›PMID 29997214›Full record

ArticleJournal of virology2018

Structural Comparison of Human Anti-HIV-1 gp120 V3 Monoclonal Antibodies of the Same Gene Usage Induced by Vaccination and Chronic Infection.

Kun-Wei Chan, Ruimin Pan, Matthew Costa, Miroslaw K Gorny, Shixia Wang, Shan Lu, Xiang-Peng Kong

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kun-Wei ChanDepartment of Biochemistry and Molecular Pharmacology, NYU School of Medicine, New York, New York, USA.
Ruimin PanDepartment of Biochemistry and Molecular Pharmacology, NYU School of Medicine, New York, New York, USA.
Matthew CostaDepartment of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Miroslaw K GornyDepartment of Pathology, NYU School of Medicine, New York, New York, USA.
Shixia WangDepartment of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Shan LuDepartment of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Xiang-Peng KongDepartment of Biochemistry and Molecular Pharmacology, NYU School of Medicine, New York, New York, USA xiangpeng.kong@med.nyu.edu.
New York University · USUniversity of Massachusetts Chan Medical School · US

Funding

Optimizing the immunogenicity of next generation polyvalent HIV vaccine formulatiU19AI082676 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LU, SHAN · 2009 to 2016
$15.8M
Vaccines to Induce Functional Antibodies Targeting the V2 Loop P01AI100151 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GORNY, MIROSLAW K · 2012 to 2017
$15.4M
Variation in HIV-1 R5 Envs: Consequences for tropism, neutralization & vaccinesP01AI082274 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LU, SHAN · 2009 to 2013
$9.7M
Protective role of V2 antibodies induced at mucosal tissues in macaquesR01AI112546 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GORNY, MIROSLAW K · 2015 to 2019
$3.1M
Production of neutralizing mAbs from HIV vaccineesR33AI087191 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI WANG, SHIXIA · 2012 to 2014
$1.4M
Production of neutralizing mAbs from HIV vaccineesR21AI087191 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI WANG, SHIXIA · 2010 to 2011
$450k
NIAID NIH HHS P01 AI082274NIAID NIH HHS P01 AI100151NIAID NIH HHS R01 AI112546NIAID NIH HHS R21 AI087191NIAID NIH HHS R33 AI087191NIAID NIH HHS U19 AI082676
6 · The paper itself

Abstract

Elucidating the structural basis of antibody (Ab) gene usage and affinity maturation of vaccine-induced Abs can inform the design of immunogens for inducing desired Ab responses in HIV vaccine development. Analyses of monoclonal Abs (MAbs) encoded by the same immunoglobulin genes at different stages of maturation can help to elucidate the maturation process. We have analyzed four human anti-V3 MAbs with the same VH1-3*01 and VL3-10*01 gene usage. Two MAbs, TA6 and TA7, were developed from a vaccinee in the HIV vaccine phase I trial DP6-001 with a polyvalent DNA prime/protein boost regimen, and two others, 311-11D and 1334, were developed from HIV-infected patients. The somatic hypermutation (SHM) rates in VH of vaccine-induced MAbs are lower than in chronic HIV infection-induced MAbs, while those in VL are comparable. Crystal structures of the antigen-binding fragments (Fabs) in complex with V3 peptides show that these MAbs bind the V3 epitope with a new cradle-binding mode and that the V3 β-hairpin lies along the antigen-binding groove, which consists of residues from both heavy and light chains. Residues conserved from the germ line sequences form specific binding pockets accommodating conserved structural elements of the V3 crown hairpin, predetermining the Ab gene selection, while somatically mutated residues create additional hydrogen bonds, electrostatic interactions, and van der Waals contacts, correlating with an increased binding affinity. Our data provide a unique example of germ line sequences determining the primordial antigen-binding sites and SHMs correlating with affinity maturation of Abs induced by vaccine and natural HIV infection.

Indexed as

AIDS VaccinesAmino Acid SequenceAntibodies, MonoclonalAntibody FormationAntibody SpecificityCrystallizationGenes, ImmunoglobulinHIV-1HIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHumansHydrogen BondingSequence AlignmentSomatic Hypermutation, ImmunoglobulinVaccinationAIDS VaccinesAntibodies, Monoclonalgp120 protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp120affinity maturationantibodygene usagegp120HIV-1structureV3V3 loop

Identifiers

PMID29997214
PMCPMC6146712
OpenAlexW2889135729

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.